Rockland Trust Co. Sells 175 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Rockland Trust Co. lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,770 shares of the biopharmaceutical company’s stock after selling 175 shares during the quarter. Rockland Trust Co.’s holdings in Gilead Sciences were worth $441,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. WINTON GROUP Ltd grew its stake in Gilead Sciences by 52.9% during the 2nd quarter. WINTON GROUP Ltd now owns 8,800 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 3,043 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Gilead Sciences by 0.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock worth $5,887,000 after acquiring an additional 522 shares during the last quarter. One Capital Management LLC increased its holdings in shares of Gilead Sciences by 36.8% during the second quarter. One Capital Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 1,560 shares in the last quarter. Citizens Financial Group Inc. RI raised its position in shares of Gilead Sciences by 36.1% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 5,984 shares of the biopharmaceutical company’s stock valued at $411,000 after purchasing an additional 1,588 shares during the last quarter. Finally, Axxcess Wealth Management LLC boosted its stake in Gilead Sciences by 10.2% in the 2nd quarter. Axxcess Wealth Management LLC now owns 19,746 shares of the biopharmaceutical company’s stock worth $1,355,000 after purchasing an additional 1,830 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on GILD shares. Robert W. Baird upped their target price on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $87.00 to $113.00 in a report on Friday, January 10th. The Goldman Sachs Group lifted their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Mizuho increased their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Stock Up 1.5 %

Gilead Sciences stock opened at $92.38 on Thursday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The stock has a market capitalization of $115.13 billion, a PE ratio of 1,026.44, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business has a 50 day simple moving average of $91.96 and a 200-day simple moving average of $83.69.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.33%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 453,734 shares of company stock worth $41,902,086. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.